文献速递中枢神经肿瘤放疗放疗物理与技术

放疗改善胶质母细胞瘤对免疫治疗药物的反应

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas.
PubMed 文献 · Adv Radiat Oncol · 2018-11-20

本文综述了胶质母细胞瘤(GBM)免疫治疗的基本原理、临床前与临床数据,以及放疗联合免疫治疗(包括免疫检查点调节剂、转化生长因子β受体抑制剂和吲哚胺-2,3-双加氧酶抑制剂)的前景与挑战。GBM 呈低免疫原性且采用多种免疫抑制策略,免疫治疗单用结果令人失望,而放疗可诱导免疫原性细胞死亡并激活T细胞浸润,为联合治疗提供依据。

要点

  • GBM 呈低免疫原性,微环境中效应T细胞少或无,非同义体细胞突变负荷和预测新抗原负荷均较低。
  • 多种免疫治疗单用结果令人失望,支持将免疫治疗与放疗联合的合理性。
  • 免疫检查点调节剂、TGF-β受体抑制剂和IDO抑制剂在临床前GBM模型中与放疗联合结果有前景,正在临床试验中进一步测试。

核心结论

  • 本综述旨在呈现GBM这一新兴互补治疗策略的基本原理,评价当前临床前和临床数据,并讨论改善抗肿瘤免疫反应所面临的未来挑战。

研究设计与样本

  • 本文为综述,检索范围未在原文中具体报告。

主要发现

  • GBM 呈低免疫原性,微环境中效应T细胞少或无,非同义体细胞突变负荷相对较低,预测新抗原负荷低。
  • GBM 利用多种免疫抑制策略。
  • 多种免疫治疗单用结果令人失望。
  • 放疗可诱导免疫原性形式的细胞死亡,伴T细胞激活和肿瘤浸润。
  • 免疫检查点调节剂、转化生长因子β受体抑制剂和吲哚胺-2,3-双加氧酶抑制剂在临床前GBM模型中与放疗联合结果有前景,正在临床试验中进一步测试。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for immunotherapy. However, GBM tends to be nonimmunogenic and exhibits a microenvironment with few or no effector T cells, a relatively low nonsynonymous somatic mutational load, and a low predicted neoantigen burden. GBM also exploits a multitude of immunosuppressive strategies. METHODS AND MATERIALS: A number of immunotherapeutic approaches have been tested with disappointing results. A rationale exists to combine immunotherapy and radiation therapy, which can induce an immunogenic form of cell death with T-cell activation and tumor infiltration. RESULTS: Various immunotherapy agents, including immune checkpoint modulators, transforming growth factor beta receptor inhibitors, and indoleamine-2,3-dioxygenase inhibitors, have been evaluated with irradiation in preclinical GBM models, with promising results, and are being further tested in clinical trials. CONCLUSIONS: This review aims to present the basic rationale behind this emerging complementary therapeutic approach in GBM, appraise the current preclinical and clinical data, and discuss the future challenges in improving the antitumor immune response.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nesseler JP, Schaue D, McBride WH, et al. Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. Adv Radiat Oncol. 2018. PMID: 31011672. doi:10.1016/j.adro.2018.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。